|
|
Volumn 67, Issue 2, 2010, Pages 93-
|
|
FDA approves kallikrein inhibitor to treat hereditary angioedema
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRADYKININ;
ECALLANTIDE;
KALBITOR;
KALLIKREIN;
PLACEBO;
UNCLASSIFIED DRUG;
ANAPHYLAXIS;
ANGIONEUROTIC EDEMA;
CHEST TIGHTNESS;
COUGHING;
DIARRHEA;
DIZZINESS;
DRUG APPROVAL;
DRUG HYPERSENSITIVITY;
DRUG INFORMATION;
DRUG LABELING;
DRUG MARKETING;
DRUG PROTEIN BINDING;
DYSPHAGIA;
DYSPNEA;
EDEMA;
FACE ERYTHEMA;
FAINTNESS;
FEVER;
FOOD AND DRUG ADMINISTRATION;
HEADACHE;
HEALTH CARE PERSONNEL;
HEART BEAT;
HOARSENESS;
HUMAN;
HYPOTENSION;
INJECTION SITE REACTION;
MEDIATOR;
NASOPHARYNX INFLAMMATION;
NAUSEA;
NERVOUSNESS;
NOTE;
PHARYNX EDEMA;
PRIORITY JOURNAL;
PRURITUS;
RHINORRHEA;
RISK ASSESSMENT;
SIDE EFFECT;
SNEEZING;
THORAX PAIN;
THROAT SWELLING;
THROAT TIGHTNESS;
TREATMENT RESPONSE;
URTICARIA;
WHEEZING;
|
|
EID: 75149165794
PISSN: 10792082
EISSN: None
Source Type: Journal
DOI: 10.2146/news100005 Document Type: Note |
|
Times cited : (30)
|
|
References (0)
|